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Abstract: The advent of immunotherapy has had a major impact on the outcome and overall survival
in many types of cancer. Current immunotherapeutic strategies typically aim to (re)activate anticancer
T cell immunity, although the targeting of macrophage-mediated anticancer innate immunity has
also emerged in recent years. Neutrophils, although comprising ≈ 60% of all white blood cells in
the circulation, are still largely overlooked in this respect. Nevertheless, neutrophils have evident
anticancer activity and can induce phagocytosis, trogocytosis, as well as the direct cytotoxic elimination
of cancer cells. Furthermore, therapeutic tumor-targeting monoclonal antibodies trigger anticancer
immune responses through all innate Fc-receptor expressing cells, including neutrophils. Indeed,
the depletion of neutrophils strongly reduced the efficacy of monoclonal antibody treatment and
increased tumor progression in various preclinical studies. In addition, the infusion of neutrophils in
murine cancer models reduced tumor progression. However, evidence on the anticancer effects of
neutrophils is fragmentary and mostly obtained in in vitro assays or murine models with reports on
anticancer neutrophil activity in humans lagging behind. In this review, we aim to give an overview
of the available knowledge of anticancer activity by neutrophils. Furthermore, we will describe
strategies being explored for the therapeutic activation of anticancer neutrophil activity.
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1. Introduction
In recent years, the implementation of cancer immunotherapy has yielded unprecedented clinical
responses in many types of cancer. Most of the strategies pursued, e.g., using so-called checkpoint
inhibitors [1] or chimeric antigen receptor T cells (reviewed in [2]), are aimed at restoring T cell anticancer
immunity. More recently, strategies to (re)activate innate immunity by the targeted (re)activation of
macrophages, such as CD47 blocking antibodies [3,4], have also entered clinical trials and have yielded
promising early clinical responses [5]. A cell type that has so far been mostly overlooked as a potential
source of anticancer immune activity is the neutrophil. The neutrophil is the predominant class of
polymorphonuclear cell (PMN)/granulocyte (comprising ≈ 95% of total PMNs) and the most abundant
cell type in the human bloodstream. Therefore, “neutrophil” will be used to describe all PMN-based
studies in this review.
Neutrophils are widely recognized as the first line of defense in infectious disease, but they also
have a clear modulatory role in cancer depending on the context and cancer stage [6,7]. Neutrophils at
early stages of tumorigenesis are antitumoral [8], whereas a predominant protumoral role has been
reported at established late stages of cancer [9]. In this respect, neutrophil infiltration associates with
Int. J. Mol. Sci. 2020, 21, 7820; doi:10.3390/ijms21217820 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2020, 21, 7820 2 of 34
poor patient survival in various cancers [10–13]. On the one hand, tumor-associated neutrophils (TANs)
have been associated with poor prognosis as has been described in for instance patients with diffuse
large B-cell lymphoma (DLBCL) [11] and gastric cancer [14]. In this setting, the neutrophil–lymphocyte
ratio (NLR) is also predictive for survival outcomes of cancer patients [15,16]. On the other hand
patients with colorectal cancer had better overall survival rates when having high levels of TANs [17,18].
As for other tumor-infiltrated immune cells such as macrophages, polarization states with distinct pro-
and antitumoral activity have been delineated for TANs that may account for this differential impact
on cancer.
The best known demarcation for neutrophils is that of N1 vs. N2 neutrophils, although by now,
up to 19 different neutrophil subtypes have been reported (as reviewed by [19]). Neutrophils of the
N2 subtype typically have tumor-promoting activity, with the key cytokine driving N2 differentiation
being transforming growth factor beta (TGF-β) [20]. N1 neutrophils on the other hand are characterized
by anticancer activity and an immunostimulatory expression profile, among others defined by high
levels of tumor necrosis factor α (TNFα), Fas, intercellular adhesion molecule 1 (ICAM-1), and a low
expression level of arginase [20,21]. The key cytokine driving N1 differentiation is interferon-beta
(IFN-β) [22]. Interestingly, N1 neutrophils can also promote T cell immunity, with evident recruitment
and activation of CD8+ T cells in tumor-bearing mice that was abrogated upon neutrophil depletion [23].
Differentation into a subtype is not a definitive state, with e.g., the blocking of TGF-β converting
mature N2 TANs to an N1 phenotype in vivo [20]. A second way to classify neutrophil subsets is
based on their density; i.e., low-density neutrophils (LDNs) or high-density neutrophils (HDNs).
Neutrophils normally seggregate into the sedimentary fraction of leukocytes with segmented nuclei,
leading to the term HDN. However, LDNs co-segregate with the mononuclear cell fraction during
density-gradient isolation, and the fraction of LDN increases during (chronic) inflamation, e.g., as seen
during auto-immunity and cancer [24]. Of note, HDNs are generally seen as antitumor, resembling N1
neutrophils, whereas LDNs are more immature and alike N2 neutrophils [24–26]
Research on neutrophils in cancer is predominantly focused on the tumor-promoting role of
N2 neutrophils in the tumor micro-environment (for an in-depth review, see [27]). Nevertheless,
neutrophils can clearly have an antitumoral impact and promote anticancer immunity. For instance,
such antitumor activity is evident from various murine models, with an injection of neutrophils in
breast carcinoma-bearing rats increasing survival from 17% to 75% [28]. Reversely, the depletion of
neutrophils in the same tumor model strongly decreased the rate of spontaneous regression from 87%
to 30% [29]. Similarly, the depletion of neutrophils increased tumor relapse rates with 70% upon topical
treatment of skin cancer-bearing mice with ingenol-3-angelate [30]. Importantly, the anticancer activity
of monoclonal antibody treatment in murine models of melanoma and breast cancer was abrogated
upon the depletion of neutrophils [31], with the re-infusion of neutrophils restoring anticancer activity.
Human neutrophils also have clear antitumor activity, with neutrophils from healthy human donors
displaying intrinsic anticancer activity toward cancer cell lines [32,33], which is an effect that is further
increased by priming with granulocyte macrophage colony-stimulating factor (GM-CSF) [33].
For the elimination of cancer cells, neutrophils have a diverse set of cytotoxic tools at their disposal.
Neutrophils can eliminate cancer cells by phagocytosis, which works most efficiently when the
targeted cell is opsonized with (therapeutic) antibodies: a process called antibody-dependent cellular
phagocytosis (ADCP). Since neutrophils are relatively small cells, they do not necessarily phagocytose
complete target cells. Instead, they may take “bites” of the cancer cell membrane in a process termed
trogocytosis. Trogocytosis leads to a loss of cell membrane integrity and, concomitantly, to cell
death. Furthermore, neutrophils can trigger direct cytotoxicity by releasing high amounts of reactive
oxygen species (ROS) or by the release of granule content, e.g., in the context of antibody-mediated
targeting (also called antibody-dependent cellular cytotoxicity (ADCC)). Degranulation releases a
host of cytotoxic molecules from primary, secondary, and tertiary granules that trigger the apoptotic
elimination of cancer cells.
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In this review, we will provide an in-depth overview of the antitumor activity of neutrophils and
on neutrophil-mediated anticancer immunotherapy. Hereto, an overview of neutrophil biology and
activation, including activation via antibody/Fc-receptor (FcR) interactions and cytokines, is given in
the context of anticancer immune responses. Subsequently, the various mechanisms and therapeutic
opportunities by which neutrophils can eliminate cancer cells will be detailed, focusing on ADCC,
ADCP, and trogocytosis (Figure 1).
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death receptor signaling that is among others 1A. stimulated by cytokines. 2. antibody-mediated
Fc-receptor (FcR) activation includes: 2A. Antibody-dependent cellular cytotoxicity (ADCC), 2B.
Antibody-dependent cellular phagocytosis (ADCP) and 2C. Trogocytosis. 3. Neutrophils trigger
adaptive immune response by directly stimulating T cells or via the stimulation of antigen-presenting
cells such as dendritic cells (DCs).
2. Direct Neutrophil-Mediated Cytotoxic Activity toward Cancer Cells; Intrinsic Anticancer
Activity via Death-Inducing Ligands of the Tumor Necrosis Factor (TNF) Superfamily
As described above, neutrophils have an intrinsic capacity to eliminate cancer cells, with various
reports detailing the neutrophil-mediated elimination of cancer cell lines without affecting normal
non-malignant epithelial or endothelial cells [32–34]. Furthermore, the injection of neutrophils isolated
from healthy rats to breast carcinoma-bearing rats increased survival by 4-fold [28]. Interestingly, the
amount of neutrophils in the circulation increased in tumor-bearing mice during tumor progression,
with an increased cytotoxic activity of HDNs isolated from tumor-bearing compared to tumor-free
animals [24]. Notably, neutrophils activated by pathogens, such as viruses and bacteria, can induce
“collateral” damage toward cancer cells. The best known example hereof is the use of Bacillus
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Calmette-Guérin (BCG) immunotherapy for the treatment of bladder cancer, with neutrophils that
respond to these bacteria also efficiently eliminating cancer cells [35]. In addition, the combination
of polyinosinic–polycytidylic acid (polyI:C), a synthetic analog of double-stranded RNA that mimics
viral infections, and inactivated viral particles suppressed melanoma tumor growth in a murine mouse
model [23]. In both settings, the anticancer effect was abrogated upon the depletion of neutrophils.
This intrinsic cytotoxic activity has been attributed to the expression of Tumor Necrosis Factor (TNF)
superfamily ligands such as Fas ligand (FasL) [34] and tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) on the surface of neutrophils [36–38]. In brief, the binding of membrane-expressed
FasL or TRAIL can cross-link and activate the death receptors Fas and TRAIL-R1 and TRAIL-R2,
respectively. Activation of these receptors triggers caspase-mediated apoptotic cell death. Indeed,
neutrophil cytotoxicity toward lung cancer cells was dependent on FasL expression, as the blocking of
Fas abrogated cytotoxicity [34]. Similarly, blocking either TRAIL or its receptors significantly inhibited
the neutrophil-mediated cell death of leukemia cells [36,38]. In addition, neutrophils release the cleaved
soluble form of TRAIL (sTRAIL), which (partly) retains cytotoxic activity.
TRAIL can also be therapeutically used to augment neutrophil anticancer activity. For instance,
we previously reported on an antibody fragment–TRAIL fusion protein that was designed to bind to
C-type lectin-like molecule-1 (CLL-1) expressed on the surface of neutrophils [39]. The binding of this
fusion protein, anti-CLL1:TRAIL, equipped neutrophils with high levels of surface TRAIL available for
triggering TRAIL-R-mediated cell death in cancer cells. Indeed, TRAIL-mediated cytotoxic activity
upon antiCLL-1:TRAIL treatment was strongly enhanced and also served to effectively potentiate
ADCC induced by therapeutic antibodies on both solid and hematological cancers [39]. Of note,
although neutrophils were reported to be sensitive to TRAIL-mediated cell death as well [37], [40],
anti-CLL1:TRAIL did not negatively impact on neutrophil cell viability. Alternatively, TRAIL can
be upregulated on the surface of neutrophils by stimulation using interferon-alpha (IFN-α) and
interferon-gamma (IFN-γ) [36,37]. For instance, the ex vivo stimulation of neutrophils isolated from
chronic myeloid leukemia (CML) patients with IFN-α led to the release of high levels of sTRAIL, and
supernatants of these cultures induced apoptosis in leukemia cell lines [36]. In line with this finding, the
serum levels of sTRAIL as well as leukocyte-associated membrane TRAIL were significantly increased
in melanoma patients upon IFN-α treatment [37]. IFN-α not only positively regulates TRAIL expression
but also sensitizes cancer cells to TRAIL-mediated apoptosis [41]. Correspondingly, circulating levels of
sTRAIL have been shown to positively correlate with patient survival in various cancers, including renal
cell and gall bladder carcinoma [42,43], although the contribution of neutrophils was not evaluated
in these studies. IFN-α treatment also protects neutrophils from TRAIL-induced apoptosis [36].
Therefore, this cytokine may be of interest to stimulate surface and soluble levels of TRAIL without
negatively affecting neutrophil viability. Of note, sTRAIL has been previously shown to only effectively
activate one of its receptors, TRAIL-R1, whereas TRAIL-R2 signaling requires membrane TRAIL or
oligomerized recombinant sTRAIL for the activation of pro-apoptotic signaling [44]. Thus, it will be
interesting to dissect the role of sTRAIL in neutrophil-dependent anticancer activity in cancer types in
relation to TRAILR1 and TRAILR2 expression.
Thus, clinical evidence for the contribution of TRAIL in neutrophil-mediated cancer cell killing has
been obtained from CML and melanoma patients, who are often treated with IFN-α. In addition, the
anticancer effect as induced by BCG immunotherapy relies on the release of sTRAIL by neutrophils [45],
with patients responding well to BCG immunotherapy having higher urinary levels of sTRAIL
compared to non-responders [35]. Therefore, the intrinsic capacity of neutrophils to kill cancer cells
at least partly relies on FasL and TRAIL expression. This can be exploited for anticancer therapy by
arming neutrophils with additional TRAIL by either the use of neutrophil-targeting TRAIL fusion
proteins or by stimulating TRAIL expression with cytokines such as IFN-α.
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Activation of Neutrophil-Mediated Anticancer Responses by Cytokines
The ability of neutrophil-activating cytokines to induce anticancer responses has been widely
recognized for decades. For instance, GM-CSF primed neutrophils killed melanoma cell lines in
co-culture experiments [33]. Similarly, murine melanoma cells that were genetically modified to secrete
GM-CSF were strongly hampered in their in vivo growth [46]. These tumors were highly infiltrated by
neutrophils, macrophages, and lymphocytes, which resulted in complete rejection in most cases. In line
with this data, mice that did not express the beta-common chain (βc) receptor, a subunit essential for
GM-CSF signaling, did not respond to vaccination with GM-CSF secreting melanoma cells [47]. Similar
data were obtained for granulocyte colony-stimulating factor (G-CSF) [48], with increased ADCC by
G-CSF primed neutrophils [46,49] and high neutrophil infiltration of cancer lesions in G-CSF secreting
tumors [48]. Of note, lung cancer cells spontaneously secrete high levels of GM-CSF and G-CSF,
which increased neutrophil longevity [50]. Further, expression levels in bronchoalveolar lavage fluid
positively correlated with alveolar neutrophil counts [50]. The consequence of this for the cancer was
not described, but it may be both tumoricidal as well as tumor promoting. In this respect, G-CSF and
GM-CSF can indeed have protumoral functions and promote the differentiation of myeloid-derived
suppressor cells, especially immunosuppressive neutrophils, from hematopoietic stem and progenitor
cells [51,52], and they can facilitate cancer metastasis [53]. Importantly, these immunosuppressive
effects were especially prominent during prolonged stimulation (3–5 days) with these cytokines [51],
which argues for the implementation of short treatment with these cytokines during cancer therapy.
In addition to the G-CSF and GM-CSF receptor, neutrophils express a multitude of cytokine
receptors that can be categorized into three big families: conventional cytokine receptors (type I and
type II), members of the interleukin 1 (IL-1)-receptors, and TNF-receptor superfamily members. All of
these may aid in anticancer immune responses by neutrophils, with e.g., cancer cells engineered to
secrete IL-2 triggering immediate neutrophil-mediated rejection of syngeneic tumors in mice [54–56]. Of
note, IL-2 dose-dependently stimulates protein and RNA synthesis in GM-CSF primed neutrophils [57]
and promotes adherence to endothelial cells [58], which may augment their activity. Furthermore, the
expression of IL-4, IL-7, IL-10, IFN-α, and TNF-α in the same cancer model was, in all cases, associated
with neutrophil as well as CD8+ T cell-mediated rejection [55]. Of these, TNF-α is of particular interest
as it was identified as a key cytokine for the cytotoxic activity of neutrophils toward breast cancer
cells [59] and increased neutrophil transmigration and nitric oxide release that promotes cancer cell
killing [60]. In line with these data, serum levels of TNF-α in patients positively correlated with
neutrophil cytotoxicity [59].
Another target for anticancer neutrophil activity is inhibition of the cytokine TGF-β, which is a
multifunctional cytokine that is best known for its immune inhibitory roles in T cell biology. TGF-β also
steers the phenotype of TANs toward an N2 pro-tumorigenic phenotype [20,61], inhibits neutrophil
degranulation [62], and reduces the efficacy of G-CSF therapy [63]. This inhibitory effect of TGF-β
on neutrophils argues for the use of TGF-β antagonists to improve neutrophil-mediated anticancer
immune responses. Indeed, the blocking of TGF-β with neutralizing TGF-β monoclonal antibody
(1D11) polarized TANs toward an N1 phenotype, yielding a significant increase in colorectal carcinoma
cell death [64]. Furthermore, TGF-β blockade increased the level of neutrophil-attracting chemokines
and increased the influx of N1 neutrophils into the tumor, with increased cytotoxic potential both
in vitro and in vivo [20]. Of note, TGF-β can also have neutrophil-stimulating activity similar to
N-Formylmethionyl-leucyl-phenylalanine (fMLP) [65]. Specifically, TGF-β has chemotaxis properties;
it stimulates H2O2 and lactoferrin release in fibrogen-adherent PMNs, where the activation goes
through the phospholipase D pathway [65]. These differential effects of TGF-β seem to depend on the
cancer stage, as it suppresses early hepatocellular carcinoma development but has tumorigenic activity
at later stages [66]. Thus, TGF-β inhibition in established late-stage malignancy is expected to promote
neutrophil anticancer activity. Furthermore, TGF-β is also a crucial inhibitor of adaptive immunity,
which may make TGF-β inhibition a double-edged sword that augments both innate and adaptive
anticancer responses.
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Interestingly, the blocking of TGF-β also restored the release of IFN-α/IFN-β in mice with mammary
tumors, resulting in tumor rejection [67]. As described above, IFN-α and IFN-β drive the differentiation
of TANs into an N1 antitumoral phenotype and trigger anticancer immunity [68,69]. Indeed, IFN-α has
a pleiotropic positive impact on anticancer immunity and has been approved by the Food and Drug
Administration (FDA) for the treatment of both solid and hematologic malignancies (reviewed by [70]),
although the exact role of neutrophils in response to therapy remains to be determined. IFN-β has
been shown to have direct cytotoxicity toward cancer cells in immune-incompetent mice [71], although
it is also used to suppress autoimmune response in multiple sclerosis. Of note, the release of IFN-α
as well as IFN-β can also be efficiently triggered by 5,6-dimethylxanthenone-4-acetic acid (DMXAA),
which is a chemotherapeutic agent that causes cancer cell death by tumor vascular disruption and
cytokine production. In this particular case, IFN-α and IFN-β are produced by macrophages [67,72].
Hence, increasing IFN-α/β levels may be used to simultaneously trigger direct tumoricidal as well as
indirect neutrophil-mediated anticancer effects, which is further increased by blocking TGF-β [67].
In addition to cytokines, there are various chemokines that attract neutrophils to the site of
infection or cancer. The best-known chemoattractant for neutrophils is IL-8, also known as CXCL8
or neutrophil-activating factor [73], which is also the main, or even only, chemokine that neutrophils
can secrete themselves to create a positive feedback loop [74]. Although its role in anticancer
immunity is still controversial, most reports claim a tumor-promoting role due to sustained neutrophil
recruitment and inflammation, promoting metastasis [75] and reducing the the efficacy of checkpoint
blockade [10,76]. Reversely, the chemokine receptor CXCR2 and its ligands CXCL1, CXCL2, and
CXCL5 play an important role in homing of neutrophils to cancer cells to limit tumor growth. In this
respect, the secretion of CXCL5 and IL-8 by renal cell carcinoma (RCC) cells recruited neutrophils and
inhibited the formation of metastases [77]. In line with these data, only RCC with a low expression
of neutrophil chemokines CXCL1, CXCL2, CXCL3, CXCL5, and IL-8 were able to metastasize. In
addition, the receptors CCR2 and CCR5 were increased in pre-metastatic lung samples, which was
probably due to expression on tumor-infiltrated neutrophils, and lung cancer cells were found to
secrete their ligands CCL2 and CCL5 [63]. Indeed, in vitro treatment with CCL2 and CCL5 stimulated
neutrophils to kill tumor cells [63]. In contrast, increased serum levels of chemokines CXCL1 and
CXCL2 in mice correlated with increasing levels of CXCR2-expressing neutrophils in the blood and
enhanced melanoma growth, with tumor growth being reduced by antibody-mediated blocking of
CXCR2 [78].
Thus, the recruitment of neutrophils via cytokines and chemokines to cancer cells can have
both anticancer as well as tumor-promoting effects, which are most likely depending on the type of
neutrophils recruited and/or factors present in the micro-environment. Therefore, when designing
cytokine-based or chemokine-based anticancer therapy with the goal of activating neutrophil-mediated
anticancer immune responses, this should be taken into account. Firstly, local concentrations in the
tumor microenvironment of the infused cytokine may heavily differ from systemic concentrations.
Indeed, mice immunized with ex vivo GM-CSF-transfected tumor cells were better protected toward
subsequent tumor challenge compared to mice immunized with parental tumor cells and the cutaneous
transfection of GM-CSF cDNA at the vaccination site, which may be the result of four times higher local
concentrations of GM-CSF in the tumor microenvironment in the first case. [79]. Furthermore, the lytic
activity of neutrophils in vitro co-cultured with tumor cells that were engineered to express GM-CSF
was 3–5 fold higher compared to parental tumor cells in which culture medium was supplemented
with GM-CSF [79]. Therefore, the targeted delivery and subsequent release of cytokines at the site
of the tumor may be of interest to increase local cytokine concentrations. Secondly, the presence
of additional cytokines in the tumor microenvironment can obviously impact on the efficacy of the
infused cytokine, as already exemplified above by the negative impact of TGF-β on G-CSF therapy.
Hence, it is imperative to consider and carefully delineate cancer type-specific microenvironmental
factors in potential cytokine/chemokine-based therapeutic approaches.
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3. FcR-Mediated Neutrophil Activation; Targeting FcγRIIa (CD32a) and FcαRI (CD89) for
Optimal Responses
Perhaps the main way that neutrophils are involved in anticancer activity is by the activation of
Fc-receptors (FcRs) upon binding by the immunoglobulin (Ig) domain of therapeutic antibodies. Most
therapeutic antibodies currently in the clinic or in clincal trials are of the immunoglobulin G (IgG)
isoform that can interact with activating Fcγ receptors (FcγRs) and trigger antibody-dependent cellular
phagocytosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC), and trogocytosis [31], [80–82].
Human neutrophils express the activating Fcy receptors, FcγRI (CD64), FcγRIIa (CD32a), FcγRIIc
(CD32c), and FcγRIIIa (CD16a) [83–86], as well as the inhibitory FcγRIIb (CD32b) [87] and FcγRIIIb
(CD16b) [83–85], [88] (Figure 2). Although CD64 is the high-affinity receptor and responsible for the
anticancer activity of IgG antibodies on natural killer (NK) cells, IgG antibody-induced signaling
on neutrophils is mainly dependent on CD32a [89], which is due to the fact that CD32a is the most
abundant activating FcγR on neutrophils (160,000 copies/cell [90]. In contrast, neutrophils express
1000 copies of CD64 [90], although the expression of CD64 is upregulated by pro-inflammatory
cytokines, such as G-CSF [91,92] and IFNγ [81,93]. In addition, neutrophils express low levels of CD16a
that contribute to the antibody-mediated activation of neutrophils [84]. Notably, polymorphisms
in CD32a (131-histidine(H)/arginine(R)) and CD16a (158 valine(V)/ phenylalanine(F)) may affect the
efficacy of antibody-based cancer therapy [94]. Specifically, the homozygous histidine (H)/arginine (R)
polymorphism at position 131 of CD32a (131 H/H) and CD16A (158 V/V) increased the response rate of
rituximab [95] and trastuzumab [96] in respectively lymphoma and breast-cancer patients, whereas
colorectal cancer patients with this specific polymorphism had a lower median progression-free survival
time when treated with cetuximab [97]. Human IgG binds better to 131 H/H than 131 R/R, which
may explain the improvement in efficacy for rituximab and trastuzumab [98]. Furthermore, a large
controled study demonstrated that the H131R and V158F genotypes did not correlate with trastuzumab
efficacy in HER2-positive breast cancer [99]. Differences in affinity for FcRs between antibodies may
impact on the correlation between therapy efficacy and FcR polymorphisms. In addition, adjuvant
treatment regimen, e.g., combination with chemotherapy, may influence the outcome of these studies.
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are either activating or inhibitory, thereby respectively stimulating or repressing neutrophil-mediated
ntibody-dependent cellular phagocytosis (ADCP), antibody-dependent cell l r cytotoxicity (ADCC),
and gocytosis. Among he activatio receptors are the immunoglobulin G (IgG)-binding FcRs; CD64,
CD32 and CD16a. In addition, neutrophils expre s the i munoglobulin A (IgA)-binding FcR CD89.
Inhibitory IgG-bindin FcRs that are expressed by neutrophils comprise CD32b a d CD16b.
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Antibodies also interact with inhibitory FcγRs on neutrophils, with FcγRIIb (CD32b) (2000 copies
per cell [90]) transmitting immunoreceptor tyrosine-based inhibitory motif (ITIM)-mediated inhibitory
signaling [87,100,101]. Furthermore, neutrophils express the low-affinity FcγRIIIb (CD16b), which
is a glycosylphosphatidylinositol (GPI)-anchored receptor lacking intracellular signaling motifs that
likely has a decoy function [101,102]. Resting human neutrophils express CD16b at a very high level
(1,400,000 copies/cell [90]), whereby IgG binding to resting neutrophils is predominantly mediated
by CD16b [103,104]. In comparison, resting neutrophils only express 160,000 copies of CD32a [90].
In line with its inhibitory function, the blocking of CD16b using a F(ab’)2 of a CD16b antibody
prominently increased both trogocytosis and ADCC induced by cetuximab and trastuzumab [88].
Of note, CD16b expression has also been shown to limit the efficacy of antibodies modified for
increased affinity for the activating CD16a receptor. Specifically, the removal of fucosyl groups (i.e.,
defucosylation or afucosylation) increases antibody affinity for the activating receptor CD16 and is a
strategy pursued to potentiate ADCC by NK cells [105–107]. However, defucosylation also increases
the affinity of antibodies for CD16b by 7 to 15 fold [88,103,105,108]. Correspondingly, defucosylated
trastuzumab had reduced neutrophil-mediated ADCC and trogocytosis activity compared to normal
trastuzumab, which was reversed by blocking CD16b [88] (Figure 3A). Similarly, an afucosylated
form of cetuximab, comprising point mutations S239D and I332E, increased the anticancer activity
of NK cells but strongly reduced the ADCC of cancer cells by neutrophils from 60% to 10% [104].
The latter was not observed when using neutrophils that lacked CD16b expression (isolated from
paroxysmal nocturnal hemoglobinuria patients) [104], again pointing toward the inhibitory function of
CD16b that may be exacerbated upon antibody engineering. In contrast, both the afucosylated CD20
antibody obinutuzumab and defucosylated rituximab did efficiently activate neutrophils [103,109],
with an enhanced induction of phagocytosis compared to the standard benchmark rituximab [103].
Of note, the clinical efficacy of obinutuzumab did not always outperform rituximab, while having
an increased risk of toxicity [110,111]. The apparent discrepancy in effects on neutrophil activity by
afucosylated/defucosylated antibodies may stem from the ability and/or preference of antibodies to
bind either the activating CD32a or inhibitory CD16b receptor. Indeed, when a defucosylated derivative
of cetuximab was modified to have enhanced affinity to CD32 as well, neutrophil anticancer activity
was restored to that of the unmodified antibody [104]. Furthermore, it was suggested that binding to
CD16b inhibits ADCC, but it may promote phagocytosis, as the GPI domain and the ectodomain are
able to modulate the signaling of other receptors within the same lipid rafts [88]. Indeed, the blocking
of CD16b using anti-CD16b F(ab’)2 fragments reduced the phagocytosis of cancer cells, bacteria, and
zymosan particles [88,103,112]. Importantly, CD16b is uniquely expressed on granulocytes and not
expressed by other types of immune cells [113,114] and may thus be an important consideration for the
design of IgG-based neutrophil targeting in cancer immunotherapy. Notably, CD16b is not expressed
in mice [113], and mouse studies may thus overestimate the therapeutic impact of CD16-targeting
antibodies compared to the human situation.
Furthermore, the outcome of IgG-mediated neutrophil anticancer activity is influenced by local
inflammatory conditions. For instance, the activation of neutrophils with G-CSF or IFN-γ upregulated
CD64 and strongly reduced the expression of CD16b [88]. Correspondingly, the inhibition of CD16b
using CD16 F(ab’)2 did not potentiate ADCC and trogocytosis by these activated neutrophils. Such
upregulation of CD64 and downregulation of CD16 has also been observed on HDNs isolated from
patients with multiple myeloma [115]. However, although CD64 is an activating FcR, these HDNs from
myeloma patients were less effective in phagocytosis compared to healthy controls, which was caused by
the increased expression of arginase-1, which is an enzyme that is immune inhibitory. Indeed, arginase-1
inhibitors reactivated the HDNs of myeloma patients [115]. Reversely, the immunosuppressive cytokine
TGF-β may in the tumor microenvironment downregulate CD64 expression, as for instance reported
for monocytes [116]. Thus, the balance of receptor expression as well as neutrophil polarization status
in the tumor microenvironment is difficult to predict. An additional layer of complexity in this respect
is the fact that CD16b can be proteolytically shed by ADAM17, which is a matrix metalloprotease
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often highly expressed in the cancer microenvironment [117]. Taken together, although the “net”
activity of defucosylated/afucosylated antibodies may be improved compared to parental antibodies
via the stronger activation of NK cells, this modification generally has a negative impact on the activity
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Figure 3. IgG versus IgA. (A) panel 1. The removal of fucose groups from antibodies
(defucosylation/afucosylation) increases affinity for FcγRs and hence increases the activation of
natural killer (NK) cells. However, neutrophils also express the inhibitory FcγR CD16b that is stronger
bound by defucosylated antibodies as well, shifting the balance toward inhibitory signaling. (A) panel
2. CD16b-blocking antibodies prevent the interaction of therapeutic defucosylated antibodies to CD16b,
shifting the balance toward activation. (B) panel 1. IgA binds with a higher affinity and stoichiometry
to CD89 than IgG to CD32a. Specifically, IgA binds in a bivalent (2:1) conformation to CD89, resulting
in the activation of four immunereceptor tyrosine-based activation motifs (ITAMs). In contrast, IgG
bi ds in mon valent (1:1) co formation to CD32a, yielding only one active ITAM motif. (B) panel 2.
Whereas neutrophils express very high levels of CD16b, a non-signaling decoy inhibitor receptor for
IgG, they do not express inhibitory FcRs for IgA.
In addition to using IgG1 formats, the specific activation of neutrophils can also be achieved by
the use of antibodies f the IgG2 iso ype. Specifically, whereas panitumumab (anti-epidermal growth
factor receptor (EGFR) IgG2) was inactive n riggering ADCC by mononucle r cells, it induced tumor
cytotoxicity when using neutrophils as ffector cells to a similar extend as zalutumumab (anti-EGFR
IgG1) [50]. In contrast, panitumumab was also ineff ctive n inducing neutrophil-mediated tumor
cell lysis in a other study, which relied on the activation of inhibitory CD16 signali g [118]. Further,
s luble IgG2 in contrast to membran -bound IgG2 does not nteract with th inhibitory receptor CD16b,
whereas both soluble as well as membra e-bound IgG1 does [119].
Another important FcR that is a potential prominen , yet less expl red, target for antibody-bas
herapeutics is FcαRI (CD89). CD89 is highly expressed on neutroph ls, alt ugh it is expressed
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≈ 2 times lower than CD32a [120], as well as on other myeloid cells [121]. CD89 is bound by
immunoglobulin A (IgA), the second most prevalent immunoglobulin in the serum reviewed by [122].
In humans, IgA is comprised of the subclasses IgA1 and IgA2, of which IgA1 is about nine times more
prevalent in serum compared to IgA2. IgA1 has a 13 amino acid insertion in the hinge region that
contains five glycosylation sites [123], whereas IgA2 itself contains a higher number of N-glycosylation
sites [124,125]. IgA2 was recently shown to have a higher affinity for CD89 on neutrophils compared
to IgA1 due to reduced N-linked terminal sialic acids, with desialylation restoring IgA1 activity
to that of IgA2 [126]. In line with these data, an IgA2 isoform of an EGFR antibody was superior
over IgA1 in recruiting neutrophils [127]. Importantly, both IgG and IgA isoforms seem to bind
equally to their target antigen, as has been shown for EGFR, with both variants blocking EGF binding
and inhibiting EGFR phosphorylation [127]. Nevertheless, in a head-to-head comparison using a
CD20 antibody of the IgG and IgA isotype, ADCC was more effectively induced by the IgA than
the IgG antibody [120]. Furthermore, neutrophil-mediated tumor cell killing was stronger using IgA
compared to IgG antibodies for various cancer antigens, e.g., epithelial cellular adhesion molecule
(EpCAM) (colon carcinoma) [128], human epidermal growth factor receptor-2 (HER-2) (mammary
carcinoma) [129], EGFR (epithelial, colorectal, and renal cell carcinoma) [130], CD30 (B- and T-cell
lymphoma) [131], HLA class II [132], and CD20 (B-cell lymphoma) in in vitro studies [127] and in vivo
studies [133,134].
In line with these studies highlighting the more prominent role of CD89, immature bone
marrow-derived neutrophils mobilized with G-CSF efficiently eliminated tumor cells via CD89, but
they did not trigger CD64-mediated anticancer responses [135]. Similarly, the use of an IgA isoform was
also superior over IgG isoforms in recruiting monocytes/macrophages as well as neutrophils [130,133].
This superior activity of IgA has been attributed to the stronger affinity of CD89 for IgA compared to
the affinity of IgG for CD32a, >107 versus 106 respectively [136,137]. Indeed, the binding of IgA to
CD89 is more stable, and in contrast to other Fc receptors, which form 1:1 complexes with the Fc regions
of their target antibodies, the interaction between CD89 and IgA1 results in the formation of a 2:1
complex [120,138]. This bivalent binding recruits four instead of one immunereceptor tyrosine-based
activation motif (ITAM) domains, yielding stronger signaling (Figure 3B; panel 1). Furthermore,
unlike IgG1-mediated FcγR signaling, the IgA-signaling pathway is not subject to the inhibition of
signaling via CD16b [88] (Figure 3B; panel 2). However, it should be noted that the serum half-life of
IgA antibodies is much shorter compared to IgGs [139], which may limit efficacy or necessitate more
frequent infusions. These problems may be resolved by engineering IgA with lower levels of terminal
galactosylation formulations with increased stability [140,141]. Furthermore, the in vivo evaluation of
IgA antibodies is more challenging than IgG antibodies as mice possess a completely different IgA
system and do not express an CD89 homologue, and hence, transgenic mouse models are required to
study the efficacy of IgA antibodies [142].
In addition, it should be noted that IgG isoforms have the critical benefit of efficiently triggering
and activating NK cell-mediated cytotoxicity, which argues for the simultaneous use of both IgA and
IgG mAbs (Figure 4; panel 1). Indeed, a combination of IgA and IgG mAbs targeting EGFR and HER2
displayed increased cytotoxicity compared to either isoform alone both in vitro as well as in vivo [143].
In addition, the use of a trastuzumab [144] or an anti-CD20 [145] tandem IgG1/IgA2 format yielded
superior activity over the parental IgG antibody by efficiently recruiting all types of FcR-expressing
immune cells. In contrast, although anti-EpCAM IgA1 induced a higher tumor-specific cell lysis than
IgG1 by purified PMNs, the combination of IgA1 and IgG1 reduced tumor cell death compared to
IgA alone [146]. Furthermore, when using whole blood as effector cells, tumor cell lysis induced by
IgG1 alone was stronger compared to the combination of IgA1 and IgG1. This discrepancy in efficay of
IgA1 and IgG1 combinations was attributed to triggering of the inhibitory receptor CD32b by IgG1,
and indeed CD32b F(ab’)2 fragments restored ADCC [146]. Furthermore, in case the intensity of
IgA-mediated triggering of CD89 on neutrophils is too low, inhibitory ITAM signaling can prevail [147].
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Alternatively, bispecific antibodies comprising a human IgG1 bispecific antibody with additional
specificity for CD89 can be exploited (Figure 4; panel 2). For instance, an IgG1-based bispecific targeting
CD20 and CD89 effectively recruited and activated CD89-positive neutrophils and macrophages
to CD20-positive cancer cells, yielding prominent in vitro and in vivo anticancer activity [148,149].
Similarly, CD89-directed bispecifics targeting CD19, major histocompatibility complex (MHC) class
II or CD30, induced the neutrophil-mediated lysis of malignant B cells [131,149,150]. In addition,
by using such bispecific IgG formats, IgG1 stability and half-life can be exploited for the effective
recruitment and activation of IgA FcRs.
In conclusion, neutrophils can be activated using IgG-based antibodies via pro-inflammatory
FcγRs CD64, CD32a, and CD16a, although this type of antibody is subject to potential inhibition by
inhibitory receptors such as CD32b and CD16b. The activation of neutrophils via the pro-inflammatory
FcαR CD89 using IgA antibodies is more effective, but it is also associated with potential drawbacks
such as poor half-life. Continued development in this field, evidenced by IgA/IgG chimeric formats or
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the bispecific IgG-based antibody formats referenced above, yield important steps forward toward
fully exploiting the antibody-mediated activation of neutrophil anticancer activity.
3.1. Neutrophil-Mediated Cytotoxic Activity toward Cancer Cells; Targeted Anticancer Activity by
Antibody-Dependent Cellular Cytotoxicity (ADCC)
In a therapeutic setting, antibody-mediated targeting of neutrophil activity to cancer antigens
can activate ADCC, which will trigger the release of reactive oxygen species (ROS) during a
so-called “oxidative burst”. In addition, the content of neutrophil granules are released, whereby
cytotoxic molecules such as elastase, myeloperoxidase, cathepsins, and defensins (primary granules),
lactoferrin, arginase, and matrix metalloprotease 9 (secondary and tertiary granules) can eliminate
the targeted cancer cell. ADCC has been shown to contribute to neutrophil-mediated cytotoxicity for
various therapeutic antibodies currently in clinical use. For instance, rituximab treatment induced
neutrophil-mediated ADCC in B cell lymphoma in in vitro assays [151], whereas cetuximab induced
neutrophil-mediated ADCC in head and neck cancer [118], skin squamous cell carcinoma [104], and
colon carcinoma [152]. The ADCC activity of cetuximab correlated with the expression level of EGFR
on the cell surface of the target cells [153]. Similar neutrophil-dependent ADCC has been reported
for antibodies targeting HER2/Neu (trastuzumab) [82,88,89], CCR4 [154], EGFR (panitumumab and
zalutumumab) [50], EpCAM [146], and CD52 (alemtuzumab) [155]. Indeed, the alemtuzumab-mediated
depletion of lymphocytes was inhibited or even abrogated in the absence of neutrophils in murine
lymphoma models [155–157]. A similar loss of ADCC activity upon treatment with rituximab was
detected upon neutrophil depletion in a mouse model [158].
In addition, although not having a direct impact on activating neutrophils, an antibody-based
activation of the complement system can stimulate neutrophil-mediated anticancer immune responses.
In brief, the cleavage products C3a and C5a that are formed during the complement cascade are
potent neutrophil chemoattractants, which increase tumor infiltration by neutrophils during antibody
immunotherapy in mice [159–162]. This neutrophil recruitment via complement is further stimulated
by treatment with β-glucans [159,161,162], which is a polysaccharide-based supplement that is also
being tested in clinical trials for the treatment of cancer [NCT00857025] [NCT00682032] [NCT03461354].
Notably, high expression levels of the inhibitory membrane-bound complement regulatory proteins on
the surface of cancer cells limit complement activation and subsequent neutrophil cytotoxicity, which
can be prevented by the use of blocking antibodies [160,163]. Thus, the optimization of antibodies for
potently activating the complement system, e.g., by engineering the Fc region to increase C1q binding
affinity [164], may positively impact on neutrophil-mediated anticancer responses.
3.2. Neutrophil-Mediated Engulfment of Cancer Cells; Antibody-Dependent Cellular Phagocytosis (ADCP)
Neutrophils are profesional phagocytes with the capability to engulf and eliminate pathogens,
cell debris, as well as cancer cells. Phagocytosis is a complex process that includes the recognition,
internalization, transport, and eventual degradation of engulfed material. Of note, the intracellular
processing of ingested material differs of neutrophils diverges from the typical endocytosis pathway such
as that used by macrophages. Specifically, as neutrophils only have a small endosomal compartment,
the content of the neutrophil phagosome is typically degraded by fusion of the phagosome with
secretory vesicles and granules [as reviewed by [165].
For the purpose of cancer immunotherapy, the antibody-mediated activation of neutrophil
phagocytosis, also called antibody-dependent cellular phagocytosis (ADCP), is of most importance.
The neutrophil-mediated phagocytosis of cancer cells has been reported for CD20-targeting antibodies
in ex vivo assays. For instance, the CD20 antibody rituximab induced the phagocytosis of B
cell lymphoma cells by isolated human neutrophils in various studies [103,109,166–168], ranging
from 38% to 60% after 24 h of incubation. Similarly, CD20-targeting antibodies obinutuzumab
and ofatumumab yielded similar levels of neutrophil-mediated phagcocytosis [103,167]. As
described above, neutrophil-mediated phagocytosis by these antibodies was enhanced by using
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a glycoengineered defucosylated form [103,109], which was attributed to differential binding to FcRs.
Similar neutrophil-mediated ADCP has been reported for trastuzumab [166] and rituximab [167].
Of note, neutrophils isolated from the spleen of leukemic mice displayed reduced phagocytic
capacity ex vivo compared to neutrophils from control animals due to reduced Toll-like receptor (TLR)
expression levels, which was restored by stimulation with IL-15 and G-CSF [169]. Indeed, myeloid
cells from human leukemia patients often also have downregulated TLR expression levels [170–172].
Interestingly, the treatment of cancer patients with G-CSF in the form of pegfilgrastim, a pegylated
recobinant form of G-CSF, is already approved to prevent neutropenia and is well-tolerated even
in combination with rituximab [173–176]. Although the overall response rate of the combination
of rituximab with pegfilgrastim did not differ from treatment with rituximab alone, the authors
mentioned a “remarkably long” duration of the remission phase and argue for a follow-up study
where rituximab monotherapy is compared one on one with the combination with pegfilgrastim. As
neutrophil counts are increased by pegfilgrastim, neutrophil-mediated ADCP may have a positive
effect on rituximab therapy. Indeed, the pre-treatment of human neutrophils with pegfilgrastim in ex
vivo assays significantly increased rituximab-induced ADCP, with a maximal increase from 15 to 40%
ADCP [168]. In addition, in an in vivo model, the addition of pegfilgrastim to rituximab treatment
strongly reduced tumor volume compared to single treatments, with all mice receiving pegfilgrastim
having increased neutrophil counts in the spleen, blood, and tumor. Thus, the addition of pegfilgrastim
to antibody therapy may not only prevent severe neutropenia, but it may also contribute to therapeutic
efficacy by enhancing ADCP by neutrophils.
Taken together, although clear ADCP has been observed using isolated human neutrophils in ex
vivo assays, it should be noted that the contribution of neutrophils to ADCP is generally not investigated
in clinical trials, and as a result, clear clinical corroboration of the importance of ADCP is lacking.
However, a strong inhibition of neutrophil ADCP due to complement activation and the presence of
excess levels of competing IgGs was reported in whole blood assays in two publications [103,167],
although in a similar third study, no difference was detected between ADCP by isolated neutrophils
and in whole blood [109]. Thus, although neutrophil-mediated ADCP can clearly occur in a preclinical
setting, studies to dilineate this effect in clinical settings are required.
3.3. Trogocytosis; Lysing Cancer Cells by Biting off Parts of the Plasma Membrane
Although the neutrophil-mediated phagocytosis of cancer cells is well documented, cancer cells
are typically larger than neutrophils (e.g., an average diameter of 12–22 µM for cancer cells vs. ≈8
µm diameter for human neutrophils, respectively [177,178]). Therefore, it is conceptually a challenge
for a small neutrophil to engulf a complete cancer cell. Indeed, neutrophils were recently reported
to not phagocytose B cell chronic lymphocytic leukemia (B-CLL) cells but rather to only perform
trogocytosis [179], a process in which parts of the plasma membrane of the target cell are taken. At
the same time, neutrophils did efficiently phagocytose small beads with a diameter of 4.5 µm [179].
Further, no phagocytic uptake of CD20 antibody-opsonized B-CLL cells was detected by purified
neutrophils, as determined using live-cell time-lapse microscopy [179]. In line with these observations,
the total cell count of B-CLL cells did not significantly decrease, despite a clear increase in the number
of PMNs that stained positive for the dye used to stain the B-CLL cells [179]. Thus, B-CLL appears to
not be phagocytosed by neutrophils, although earlier studies did confirm the capacity of neutrophils to
phagocytose not only by flow cytometry but also by confocal microscopy or microscopic analysis of
cytospin [103,109,167]. The sequential uptake of membrane parts by neutrophils can eventually trigger
loss of membrane integrity and lead to cell lysis, which is a type of cell death called “trogoptosis” [82].
Trogocytosis by neutrophils has been demonstrated in vitro for various clinically used therapeutic
antibodies, i.e., antibodies directed at CD22 (epratuzumab) [180], HER2 (trastuzumab) [82], EGFR
(cetuximab) [82], and CD20 (rituximab and obinutuzumab) [179], with rituximab proving to be more
efficient in inducing trogocytosis than obinituzumab.
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Importantly, neutrophils containing a piece of HER2-positive membrane were detected in biopsies
of breast cancer patients using immunohistochemistry as well as flow cytometry [82]. This finding
provides evidence for the potential clinical relevance of neutrophil-mediated trogocytosis. Furthermore,
in a murine melanoma model, trogocytosis was also demonstrated using the CD47-blocking peptide
SSL6, in which active trogocytosing neutrophils were detected using intravital microscopy [82]. Thus,
trogocytosis seems to be one of the mechanisms for neutrophils to eliminate cancer cells that may be
relevant for clinically used therapeutic antibodies. Of note, the efficiency of trogocytosis is, similar
to phagocytosis, increased by neutrophil-activating stimuli, such as by innate checkpoint inhibition
(described in Section 2D) [82].
However, trogocytosis does not always result in cell death, as CD20 antibodies triggered the
trogocytosis of B-CLL cells without affecting cell viability [179]. In this respect, trastuzumab-opsonized
breast cancer cells that died via trogocytosis lost a significantly larger percentage of their plasma
membrane compared to cells that underwent trogocytosis yet survived the treatment [82]. Consequently,
the amount of “bites” and the size of the eventual “hole” in the plasma membrane seems to determine
whether a cell will lyse due to trogocytosis or not. Furthermore, antibody-mediated trogocytosis is
also known to downregulate the surface expression of target antigens on cancer cells [82,179–181].
For instance, treatment with rituximab and obinutuzumab down-regulated the expression of CD20 in
B-CLL cells due to neutrophil-mediated trogocytosis [179]. Furthermore, HER2/Neu expression was
reduced upon neutrophil trogocytosis of breast cancer cells opsonized with tastuzumab [82]. Although
these findings implicate trogocytosis in the escape of cancer cells from therapy due to a loss of target
antigen, neutrophil-mediated downregulation of CD38 on lymphoma cells during daratumumab
treatment was detected in both responders as well as non-responders [182]. Thus, it remains to be
determined whether trogocytosis can contribute to resistance to antibody therapy due to a loss of
antigen expression or not.
For trogocytosis to occur, both adhesion molecule and FcγR-mediated interaction appears to
be required, with both interactions facilitating the repeated close contacts between neutrophil and
target cells characteristic for trogocytosis [82,179,183]. Indeed, the induction of trogocytosis in cancer
cells is dependent on both CD18/CD11b and FcγR interactions, with CD18, CD11b, and FcR-blocking
antibodies reducing trogocytosis [82]. Furthermore, the inhibition of downstream FcγR signaling
pathways using syk inhibitors abolished cancer cell trogocytosis [82]. Similarly, using a pharmacological
inhibitor library screen, trogocytosis was found to rely on the activity of phosphoinositol-3 kinase (PI3K),
myosin light-chain kinase, and intracellular calcium flux. Of note, the inhibition of these signaling
molecules also suppresses neutrophil-mediated ADCC [82], suggesting that trogocytosis could be a
part of ADCC-mediated anticancer activity by neutrophils. Similar to neutrophil-mediated ADCC,
trogocytosis is also inhibited by CD16b interaction of the opsonizing antibody, with treatment in the
presence of blocking CD16 F(ab’)2 increasing the level of trogocytosis [88]. Cell death due to trogocytosis
did not require the release of granules (containing granzymes and perforins), as the pharmacological
inhibition of perforins did not affect cell death [183]. In line with these data, neutrophils from patients
with a genetic mutation that abrogates the release of granules were not impaired in their ability to
induce antibody-mediated trogocytosis [82,183]. Similarly, neutrophils incapable of producing reactive
oxygen species were still able to induce trogocytosis, with a pharmacological inhibition of nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase not affecting cell death [183]. Thus, cell death due
to trogocytosis is more likely a separate cytotoxic effector mechanism employed by neutrophils to
eliminate cancer cells.
Taken together, neutrophils can kill cancer cells via trogocytosis, and this mechanism is likely to
be predominant over phagocytosis when the target cell is too big for complete ingestion. The exact
contribution of this process to anticancer activity of therapeutic antibodies remains to be identified,
although it is likely that trogocytosis occurs in patients during antibody therapy.
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3.4. Augmenting Neutrophil-Mediated ADCP and ADCC by Targeting of Innate Immune Checkpoints
In recent years, the targeting of checkpoints in T cell immunity has taken center stage. Similarly,
neutrophil activity is kept in check by immunoregulatory checkpoints that can be exploited by cancer
to silence neutrophil cytotoxicity. One of the best established in this respect is the overexpression of
the “don’t eat me” signal CD47 in cancers. CD47 is a 50-kDa membrane glycoprotein that is expressed
by virtually all cells in the human body, where it functions as “marker of self”. By binding to signal
regulatory protein α (SIRPα), among others expressed by neutrophils, it inhibits phagocytic uptake
or trogocytosis (Figure 4B; panel 1). Cancer cells hijack this inhibitory CD47–SIRPα pathway by
overexpressing CD47, which is associated with poor prognosis in both solid [184,185] and hematological
cancers [3,186]. Furthermore, significantly lower CD47 expression levels were detected on breast cancer
cells of human patients that responded with a complete response after trastuzumab plus vinorelbine
therapy [187]. Furthermore, in DLBCL patients treated with standard therapy (rituximab–CHOP;
cyclophosphamide, doxorubicin, vincristine, and prednisone), the high mRNA expression of CD47
associated with poor surival in the aggressive non Germinal Center B cell subtype (non-GCB) [188].
Thus, the overexpression of CD47 by cancer cells prevents elimination by myeloid cells and reduces the
efficacy of antibody immunotherapy. Therefore, blocking CD47 is a promising therapeutic approach to
augment the neutrophil-mediated killing of cancer cells (Figure 4B; panel 2). Indeed, F(ab’)2 fragments
of the CD47-blocking antibody B6H12 enhanced neutrophil-mediated ADCC by trastuzumab from 40%
by trastuzumab alone to 80% upon combination treatment, whereas the CD47 F(ab’)2 fragment alone
had no effect [187]. Similarly, the knock-down of CD47 also potentiated neutrophil-mediated ADCC in
these studies. Correspondingly, SIRPα blocking agents also increased neutrophil-mediated anticancer
effects, with antibody KWAR23 promoting the neutrophil-mediated phagocytic removal of lymphoma
cells by rituximab and breast cancer cells by trastuzumab [166]. In addition, in vivo, the combination
of KWAR23 and rituximab or KWAR23 and vorsetuzumab (anti-CD70) reduced tumor growth and
led to partial or complete remission in 67% of the animals. Here, the depletion of either neutrophils
or macrophages increased tumor growth, highlighting the relevance of both cell populations [166].
Similarly, mice treated with both rituximab and an anti-mouse SIRPα antibody reduced lymphoma
growth in a xenograft model, resulting in prolonged survival [189]. In addition, a humanized form of
this antibody increased neutrophil-mediated trogocytosis as induced by rituximab, increasing from
30% with rituximab only to 60% in combination with SIRPα mAb, although SIRPα-only control was
lacking [189]. In addition to antibodies, the SIRPα/CD47 axis can be blocked by the use of recombinant
SIRPα protein, whereby the exogenously added SIRPα protein interacts with endogenous CD47 on
cancer cells, thereby preventing interaction with endogenous SIRPα expressed on phagocytes. Indeed,
the dual signaling protein SIRPα-4-1BB blocked the interaction of SIRPα with CD47 and induced
in vitro neutrophil- and macrophage-mediated phagocytosis of cancer cells [190].
Of note, different SIRPα variants are expressed among the human population, with SIRPα1
and SIRPαBIT being the most frequent allele among European, Admixed American, and African
populations [89,186,188]. Although there were no differences detected in the ADCC capacity of
neutrophils between the different SIRPα genotypes [89], the anticancer efficacy of SIRPα blocking
therapy is absent when targeting the wrong SIRPα variant, as an antibody specific for SIRPα1 only
promoted trastuzumab-induced ADCC when using neutrophils from α1/α1-homozygous donors [187].
Hence, pan-SIRPα antibodies that recognize all SIRPα variants have been developed, with similar
increased neutrophil-mediated anticancer effects in the presence of therapeutic antibodies [189]. Thus,
blocking the CD47-SIRPα axis can increase the therapeutic effect of antibody immunotherapy at least
partly by increasing neutrophil activity. Of interest, blocking of the CD47–SIRPα with an IgA antibody
also potentiated neutrophil-mediated ADCC and trogocytosis in vitro and inhibited tumor growth [191],
with the IgA-based antibody being more potent in neutrophil activation than an IgG-based antibody.
However, CD47 expression on neutrophils itself is required for neutrophil transmigration. Indeed,
both CD47 and SIRPα targeting blocking antibodies inhibit fMLP, IL-8, or TNFα-induced migration of
neutrophils through collagen-coated filters and epithelial cell layers [192–194]. This argues for a more
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specific targeting of CD47 at the site of the cancer cell, thereby possibly preventing inhibitory effects on
neutrophils’ transmigration. In this respect, the bispecific tandem single-chain variable fragment (scFv)
RTX-CD47 induced the phagocytosis of CD20-expressing, but not CD20-negative B cell lymphoma cell
lines by neutrophils [195]. This therapeutic activity required simultaneous binding to CD20 and CD47
and was not detected in single CD47-positive cells [195]. Several other IgG-based CD47-targeting
bispecific antibodies have been developed, among others CD20-CD47 [196] and CD70-KWAR23 [166]
CD47-CD19 [197,198], CD47-MSLN [197], CD47-PDL1 [199,200], and PD-L1-SIRPα [201]. However,
the impact of these bispecific antibodies on neutrophil-mediated phagocytosis and trogocytosis
has not been delineated yet. Of note, since the RTX-CD47 bispecific antibody format lacks an Fc
domain, the induction of phagocytosis was solely due to the inhibition of the CD47–SIRPα axis.
Indeed, whereas initially the presence of an intact Fc domain was reported to be needed for CD47
antibody-mediated phagocytosis [186,187], we and others clearly demonstrated that CD47 blocking
did not require the presence of an Fc domain [186,195,202]. Indeed, equal levels of phagocytosis
were detected when using a F(ab′)2 fragments of CD47 or SIRPα blocking antibodies compared to
Fc-containing antibodies [186,195]. Notably, CD47-mediated phagocytosis also did not depend on
cancer cell expression of the pro-phagocytic molecule SLAMF7 [202], as reported before in an earlier
paper [202].
In addition to CD47/SIRPα, other immunomodulatory proteins may be of interest to target for
improved neutrophil activity. An interesting example hereof is siglec-9, which is a member of the
sialic acid-binding immunoglobulin-type lectins (siglecs) that is prominently expressed on neutrophils.
Binding to siglec-9 induces inhibitory signaling in neutrophils and prevents the “uptake of self” by for
instance erythrocytes [203]. Cancer cells highjack this inhibitory pathway by overexpressing siglec-9
ligands and/or via hyper-sialylation of siglec-9 ligands [204]. Indeed, antibody-mediated blocking of
siglec-9 activated neutrophils and increased tumor cell killing [204]. Of note, mucin-1, a glycoprotein
often overexpressed in cancer, is a known binding partner of siglec-9, and this interaction leads to
cancer cell growth [205]. Hence, siglec-9-blocking strategies may work as a “double edged sword”
by releasing the brake on neutrophil activation and inhibiting mucin-1-mediated cancer cell growth.
Interestingly, siglec-9 also inhibits T cell activity [206,207] and may, therefore, potentiate both innate
and adaptive anticancer immune responses.
In conclusion, the targeting of innate immune checkpoints represents a promising approach to
increase the uptake of cancer cells by phagocytes and augment cancer immunotherapy with therapeutic
antibodies. Indeed, CD47 and SIRPα blocking strategies are being studied in many ongoing trials and
have demonstrated promising therapeutic effects in various malignancies, including DLBCL [5,208],
AML, [3] and Sezary syndrome [209], with acceptable safety and toxicity profiles [NCT02216409]
[NCT02953782] [NCT02678338] [NCT02953509] [NCT03248479] [NCT03013218] [NCT02663518].
Furthermore, additional targets such as siglec-9 are being explored and moving toward clinical
evaluations. However, to date, the majority of those studies are focused on macrophages-mediated
effects. Nevertheless, preclinical data highlight the contribution of neutrophils to the anticancer activity
of checkpoint targeting with confirmation of this activity in clinical settings being awaited.
4. Neutrophil-Mediated Induction of Adaptive Anticancer Immune Responses
Neutrophils were initially classified as “simple” innate immune cells important for the immediate
elimination of pathogens. However, evidence has emerged that neutrophils can also present antigens
to T cells in the context of MHC. Specifically, neutrophils in early-stage lung cancer patients had
characteristics of antigen-presenting cells and were capable of cross-presenting tumor antigens to T
cells, leading to the development of anticancer T cell responses [210]. In addition, upon phagocytosing
B cell lymphoma cells treated with anti-CD20 antibodies, the expression of MHC class II on neutrophils
increased [109], which may facilitate antigen presentation to helper T cells. Although these are to
our knowledge the only studies of antigen presentation by neutrophils in cancer to date, antigen
presentation by neutrophils and the concomitant mounting of T cell immunity has been delineated
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in various non-cancer related studies as well [211–215]. In addition, neutrophils can modulate the
activity of other antigen-presenting cell (APCs) such as DCs as initially demonstrated in the context of
infections and Crohn’s disease [216–220]. In the context of cancer, the intra-tumoral injection of CpG
oligonucleotides-B (CpG-B) inhibited tumor growth and triggered an initial strong influx of activated
neutrophils into the tumor, followed by DC activation/maturation and induction of T cell-mediated
anticancer immunity [221]. Importantly, the depletion of neutrophils hampered the tumoricidal effect
of CpG-B treatment, leading to loss in DC activation/maturation and a reduced number of CD8+ T
cells in tumor tissue and tumor-draining lymph nodes.
Currently, most evidence on the role of neutrophils in T cell immunity has been obtained in the
context of microbial infections. In brief, the early recruitment of neutrophils to the site of infection,
especially in case of the airways, aids the efficacy of subsequent T cell responses [222–224]. In addition,
CD8+ T cell responses are sustained by neutrophil help [225]. Similar neutrophil-dependent T cell
activation has been described in recent studies in cancer. For instance, during tumor-take experiments
in mice (in a G-CSF secretion colon cancer model), tumors were first infiltrated by neutrophils, followed
by macrophages and T cells, respectively. The depletion of neutrophils strongly reduced CD8+ T
cell infiltration and associated with tumor progression [226]. Similarly, the inoculation of G-CSF or
GM-CSF secreting cancer cells in mice activated neutrophils, which was followed by the induction of T
cell responses [47,49]. Furthermore, neutrophil depletion prevented the induction of T cell responses in
melanoma-bearing mice, again abrogating antitumor immunity and leading to tumor progression [23].
In line with these data, the co-culture of CD8+ T cells isolated from autologous peripheral blood
or tumor specimens with TANs isolated from colon carcinoma [227] augmented T cell proliferation,
activation, and IFN-γ secretion compared to isolated T cell cultures. Similarly, TANs isolated from
early-stage lung cancer patients induced the proliferation of T cells isolated from healthy donors of both
CD4+ and CD8+ subsets [8]. Furthermore, in co-cultures with neutrophils, CD3/CD28-activated T cells
differentiated more into a “central memory” phenotype, increasing from 19% in CD8+ monocultures
to 45% in CD8+ co-cultured with neutrophils, which is a phenotype essential for anticancer immune
responses [228]. In contrast to the above, mature neutrophils of multiple myeloma patients significantly
decreased T cell proliferation upon triggering the CD3 receptor using a bispecific antibody, which was
not observed when using neutrophils from healthy donors [229]. However, only the level of mature
neutrophils, which had increased TGF-β signaling suggesting being N2 neutrophils, correlated with
prognosis in these patients.
In addition, the interaction between neutrophils and T cells increased the level of co-stimulatory
molecules (i.e., 4-1BBL, OX40L, CD54, CD86) on the neutrophil surface, whereby T cell proliferation and
activation was stimulated [8]. Indeed, the presence of blocking antibodies against these upregulated
costimulatory molecules partly (CD54, CD86) or completely (OX40L, 4-1BBL) inhibited the stimulatory
effect of TANs on T cell responses. In addition, TANs strongly suppressed protumoral IL-17 secreting
γδ T cells in a murine model of melanoma and hepatocellular carcinoma [230]. Interestingly, in colon
carcinoma patient samples, neutrophils frequently colocalized with CD8+ T cells in tumor regions.
This combined tumor infiltration associated with a better prognosis than infiltration by CD8+ T cells
alone [227], thus providing initial proof for the clinical relevance of neutrophil/CD8+ T cell interactions
in cancer.
In addition, neutrophils release various pro-inflammatory mediators, e.g., cytokines and granule
contents, that may impact on the development of adaptive anticancer immunity [as reviewed by [231].
For instance, the release of human neutrophil peptides, lactoferrin, α-defensins, and LL-37 are generally
reported as having an activating effect on T cell immunity, whereby lactoferrin promotes the recruitment
and activation of APCs [232] and α-defensins dose-dependently attract monocytes [233] and promote
DC and T cell infiltration [234]. Furthermore, neutrophil-derived IFN-γ may orchestrate the cross talk
with T cells in antitumor response [235]. In contrast, myeloperoxidase (MPO), elastase, and arginase
mainly have a suppressive impact on T cell immunity, whereby elastase sheds IL-2 and IL-6 receptors on
T cells [236], and arginase can result in the downregulation of TCRζ [237]. In addition, neutrophils can
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produce so-called “neutrophil exracellular traps” (NETs), which are extracellular neutrophil-derived
structures composed of DNA decorated with antimicrobial peptides derived from neutrophil granules.
These NETs are used by neutrophils to trap and subsequently kill pathogens and are typically attributed
a pro-tumorigenic role in cancer. In contrast, NETs are also able to directly prime T cells, whereby
the responsiveness of T cells toward their antigens is increased [238]. Furthermore, NET-producing
neutrophils infiltrated into tumors of head and neck squamous cell carcinoma patients and were
associated with better survival [239]. Thus, NETs may form a platform for T cell priming, and in spite
of the typical protumoral role, they may in specific cases contribute to anticancer immune responses.
Taken together, neutrophils can function as antigen-presenting cells themselves or stimulate other
APCs to activate T cells. Furthermore, they can directly stimulate T cells by either cell/cell contact or
secreted factors. Therefore, neutrophils seem to be more than “simple” innate immune cells, being
involved in the initiation of efficient adaptive anticancer immune responses.
5. Conclusions and Perspectives
As apparent from this review, neutrophils have prominent anticancer activity that can be exploited
for cancer immunotherapy. Unfortunately, to date, the clinical evidence for the relevance of neutrophils
in the fight against cancer remains limited due, on the hand, to the fact that most studies focus on
the effects of macrophages and T cells and do not investigate the contribution of neutrophils. On the
other hand, current treatment strategies are also not designed with neutrophils in mind, with the
extensive focus on IgG isotype antibodies as the prominent example. Indeed, the full potential and
therapeutic relevance of neutrophils will become only apparent as neutrophil-tailored drugs, such as
IgA based therapeutic mono- and bispecific antibodies, enter clinical practice. In this respect, it has
become apparent from the field of virology that neutrophils are critical players in the development of
both humoral and T cell-mediated immunity against viral infections during antibody treatment and
vaccination [240]. In line with this, a neutrophil-mediated induction of anticancer T cell immunity is
also increasingly recognized as detailed in this review. Thus, with increasing knowledge taking the
neutrophil into account for cancer immunotherapy becomes ever more important for the effective
induction of innate and adaptive anticancer immunity.
Importantly, neutrophils found in the established tumor microenvironment are often attributed
with immune inhibitory effects, which could be targeted to revert neutrophil activity. Interesting in this
respect is the finding that the adaptive immune checkpoint programmed death-ligand 1 (PD-L1) also
has a regulatory effect on TANs, with PD-L1 on TANs inhibiting T and NK cell responses [241,242]. In
line with this finding, the PD1–PD-L1-axis also directly blocks neutrophil cytotoxicity, which is an
effect that was reversed by the blocking of neutrophil PD-L1 [243]. Thus, neutrophils may be involved
in the (re)induction of T cell-mediated immunity upon PD-1 checkpoint therapy. Interestingly, TANs
were also shown to secrete high levels of arginase, which is an enzyme that cleaves the semi-essential
amino acid L-arginine that is critical for lymphocyte proliferation and function [244,245]. High arginase
levels in the tumor tissue and serum of cancer patients associate with dampened T cell-mediated
immune responses and correlate with disease progression [245–247]. Furthermore, tumor cells secrete
the N2-promoting cytokine TGF-β [65,248] or stimulate other cells to produce TGF-β [249], and
mesenchymal stromal cells can inhibit neutrophil effector functions [250] and transform neutrophils
into a T-cell-suppressive phenotype [251]. Any of these neutrophil-inhibitory features may be a target
for immunomodulatory strategies to convert the TANs back into “tumor killers” that drive antitumor
innate and adaptive immunity.
Notably, in the design of such neutrophil-based immunotherapy, it is imperative to consider
the often detrimental effects of standard cytotoxic therapy on neutrophils, frequently leading to
neutropenia in cancer patients undergoing treatment. Therefore, the dosing and timing of cytotoxic
and neutrophil-targeted therapeutic strategies is pivotal to ensure an optimal window of therapy.
In this respect, the infusion of ex vivo expanded neutrophils to overcome neutropenia, as has e.g.,
been explored in early clinical trials using neutrophils expanded from CD34+ hematopoietic stem
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cells [252,253], may well be combined with immunomodulatory strategies that ensure an anticancer
polarization of neutrophils, such as CRISPR/Cas9 gene editing of N2-polarizing transcription factors.
Such gene editing of hematopoietic stem cells can be achieved with high efficiency [254], with
proof-of-concept for the effective modification of neutrophil activity recently generated for severe
congenital neutropenia using ELANE knock-out [255] that in phagocytic functions, ROS production,
and chemotaxis was similar to healthy donors.
Another emerging approach of interest is the use of neutrophils as carriers for drug-containing
nanoparticles, since neutrophils are uniquely able to penetrate into the tumor microenvironment. For
instance, neutrophils ex vivo loaded with liposomes containing paclitaxel suppressed postoperative
glioma recurrence and increased survival in mice [256]. In addition, the injection of nanoparticles 24
h after antibody TA99 (specific for gp75) administration increased the neutrophil and nanoparticle
accumulation in the tumor, whereby TA99 guided neutrophils into the tumor via ADCC. This treatment
resulted in increased survival rates and has the advantage that it does not require ex vivo particle
loading [257]. Further, neutrophils can be recruited to the tumor site by inducing an inflammatory
response using a photosensitizer. Indeed, the combination of photosensitizer and CD11b-targeting
nanoparticles carrying a photothermal therapeutic resulted in the elimination of tumor cells and
prolonged survival of lung cancer bearing mice [258]. In a similar approach, neutrophil membranes
can be used to deliver nanoparticles to the tumor [259]. Of note, in all of these studies, the loading of
nanoparticles did not negatively impact on neutrophil functionality. Thus, such nanoparticle-based
strategies may even be combined with ex vivo expanded neutrophils to equip such neutrophils with
additional anticancer activity.
In conclusion, with the increasing understanding of the contribution of neutrophils to anticancer
immune responses, strategies tailored to more efficiently exploit neutrophil-mediated responses are
being developed toward clinical application and are anticipated to translate into the development of
effective innate and adaptive anticancer immunity.
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29. Jaganjac, M.; Poljak-Blazi, M.; Žarković, K.; Schaur, R.J.; Zarkovic, N. The involvement of granulocytes in
spontaneous regression of Walker 256 carcinoma. Cancer Lett. 2008, 260, 180–186. [CrossRef]
30. Challacombe, J.M.; Suhrbier, A.; Parsons, P.G.; Jones, B.; Hampson, P.; Kavanagh, D.; Rainger, G.E.; Morris, M.;
Lord, J.M.; Le, T.T.T.; et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy
with ingenol-3-angelate. J. Immunol. 2006, 177, 8123–8132. [CrossRef]
31. Albanesi, M.; Mancardi, D.A.; Jönsson, F.; Iannascoli, B.; Fiette, L.; Di Santo, J.P.; Lowell, C.A.; Bruhns, P.
Neutrophils mediate antibody-induced antitumor effects in mice. Blood 2013, 122, 3160–3164. [CrossRef]
[PubMed]
32. Yan, J.; Kloecker, G.; Fleming, C.; Bousamra, M.; Hansen, R.; Hu, X.; Ding, C.; Cai, Y.; Xiang, D.; Donninger, H.;
et al. Human polymorphonuclear neutrophils specifically recognize and kill cancerous cells. OncoImmunology
2014, 3, e950163. [CrossRef] [PubMed]
33. Dissemond, J.; Weimann, T.K.; Schneider, L.A.; Schneeberger, A.; Scharffetter-Kochanek, K.;
Goos, M.; Wagner, S.N. Activated Neutrophils Exert Antitumor Activity Against Human
Melanoma Cells: Reactive Oxygen Species-Induced Mechanisms and Their Modulation by
Granulocyte-Macrophage–Colony-Stimulating Factor. J. Investig. Dermatol. 2003, 121, 936–938. [CrossRef]
[PubMed]
34. Sun, B.; Qin, W.; Song, M.; Liu, L.; Yu, Y.; Qi, X.; Sun, H. Neutrophil Suppresses Tumor Cell Proliferation
via Fas/Fas Ligand Pathway Mediated Cell Cycle Arrested. Int. J. Biol. Sci. 2018, 14, 2103–2113. [CrossRef]
[PubMed]
35. Ludwig, A.T. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand: A Novel Mechanism for Bacillus
Calmette-Guerin-Induced Antitumor Activity. Cancer Res. 2004, 64, 3386–3390. [CrossRef] [PubMed]
36. Tecchio, C.; Huber, V.; Scapini, P.; Calzetti, F.; Margotto, D.; Todeschini, G.; Pilla, L.; Martinelli, G.; Pizzolo, G.;
Rivoltini, L.; et al. IFNa-stimulated neutrophils and monocytes release a soluble form ofTNF-related
apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 2004,
103, 3837–3844. [CrossRef] [PubMed]
37. Kamohara, H.; Matsuyama, W.; Shimozato, O.; Abe, K.; Galligan, C.; Hashimoto, S.-I.; Matsushima, K.;
Yoshimura, T. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL
receptor expression in human neutrophils. Immunology 2004, 111, 186–194. [CrossRef] [PubMed]
38. Koga, Y.; Matsuzaki, A.; Suminoe, A.; Hattori, H.; Hara, T. Neutrophil-Derived TNF-Related
Apoptosis-Inducing Ligand (TRAIL). Cancer Res. 2004, 64, 1037–1043. [CrossRef]
39. Wiersma, V.R.; De Bruyn, M.; Shi, C.; Gooden, M.J.; Wouters, M.C.; Samplonius, D.F.; Hendriks, D.;
Nijman, H.W.; Wei, Y.; Zhou, J.; et al. C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments
the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated
cytotoxicity. mAbs 2015, 7, 321–330. [CrossRef]
40. Renshaw, S.A.; Parmar, J.S.; Singleton, V.; Rowe, S.J.; Dockrell, D.H.; Dower, S.K.; Bingle, C.D.; Chilvers, E.R.;
Whyte, M.K.B. Acceleration of Human Neutrophil Apoptosis by TRAIL. J. Immunol. 2003, 170, 1027–1033.
[CrossRef]
41. Shigeno, M.; Nakao, K.; Ichikawa, T.; Suzuki, K.; Kawakami, A.; Abiru, S.; Miyazoe, S.; Nakagawa, Y.;
Ishikawa, H.; Hamasaki, K.; et al. Interferon-α sensitizes human hepatoma cells to TRAIL-induced apoptosis
through DR5 upregulation and NF-κB inactivation. Oncogene 2003, 22, 1653–1662. [CrossRef] [PubMed]
42. Toiyama, D.; Takaha, N.; Shinnoh, M.; Ueda, T.; Kimura, Y.; Nakamura, T.; Hongo, F.; Mikami, K.; Kamoi, K.;
Kawauchi, A.; et al. Significance of serum tumor necrosis factor-related apoptosis-inducing ligand as a
prognostic biomarker for renal cell carcinoma. Mol. Clin. Oncol. 2012, 1, 69–74. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 7820 22 of 34
43. Liu, Z.; Kemp, T.J.; Gao, Y.-T.; Corbel, A.; McGee, E.E.; Roa, J.C.; Wang, B.; Araya, J.C.; Shen, M.-C.; Rashid, A.;
et al. Circulating Levels of Inflammatory Proteins and Survival in Patients with Gallbladder Cancer. Sci. Rep.
2018, 8, 5671. [CrossRef] [PubMed]
44. Wajant, H.; Moosmayer, D.; Wüest, T.; Bartke, T.; Gerlach, E.; Schönherr, U.; Peters, N.; Scheurich, P.;
Pfizenmaier, K. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective
surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 2001, 20, 4101–4106.
[CrossRef]
45. Kemp, T.J.; Ludwig, A.T.; Earel, J.K.; Moore, J.M.; VanOosten, R.L.; Moses, B.; Leidal, K.; Nauseef, W.M.;
Griffith, T.S. Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Gueérin (BCG) results in
the release of functional soluble TRAIL/Apo-2L. Blood 2005, 106, 3474–3482. [CrossRef]
46. Armstrong, C.A.; Botella, R.; Galloway, T.H.; Murray, N.; Kramp, J.M.; Song, I.S.; Ansel, J.C. Antitumor
effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res.
1996, 56, 2191–2198. [PubMed]
47. Zarei, S.; Schwenter, F.; Luy, P.; Aurrand-Lions, M.; Morel, P.; Kopf, M.; Dranoff, G.; Mach, N. Role of GM-CSF
signaling in cell-based tumor immunization. Blood 2009, 113, 6658–6668. [CrossRef] [PubMed]
48. Stoppacciaro, A.; Forni, G.; Colombo, M.P. Different tumours, transduced with different cytokine genes as
G-CSF and IL-2, show inhibition of tumour take through neutrophil activation but differ in T cell functions.
Folia Biol. 1994, 40, 89–99.
49. Schneider-Merck, T.; Van Bueren, J.J.L.; Berger, S.; Rossen, K.; Van Berkel, P.H.; Derer, S.; Beyer, T.; Lohse, S.;
Bleeker, W.K.; Peipp, M.; et al. Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively
Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage.
J. Immunol. 2010, 184, 512–520. [CrossRef] [PubMed]
50. Wislez, M.; Fleury-Feith, J.; Rabbe, N.; Moreau, J.; Cesari, D.; Milleron, B.; Mayaud, C.; Antoine, M.;
Soler, P.; Cadranel, J. Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor and Granulocyte
Colony-Stimulating Factor Prolong the Survival of Neutrophils Infiltrating Bronchoalveolar Subtype
Pulmonary Adenocarcinoma. Am. J. Pathol. 2001, 159, 1423–1433. [CrossRef]
51. Casbon, A.-J.; Reynaud, D.; Park, C.; Khuc, E.; Gan, D.D.; Schepers, K.; Passegué, E.; Werb, Z. Invasive
breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive
neutrophils. Proc. Natl. Acad. Sci. USA 2015, 112, E566–E575. [CrossRef] [PubMed]
52. Wu, W.-C.; Sun, H.-W.; Chen, H.-T.; Liang, J.; Yu, X.-J.; Wu, C.; Wang, Z.; Zheng, L. Circulating hematopoietic
stem and progenitor cells are myeloid-biased in cancer patients. Proc. Natl. Acad. Sci. USA 2014, 111,
4221–4226. [CrossRef] [PubMed]
53. Kowanetz, M.; Wu, X.; Lee, J.; Tan, M.; Hagenbeek, T.J.; Qu, X.; Yu, L.; Ross, J.; Korsisaari, N.; Cao, T.; et al.
Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+
granulocytes. Proc. Natl. Acad. Sci. USA 2010, 107, 21248–21255. [CrossRef] [PubMed]
54. Cavallo, F.; Giovarelli, M.; Gulino, A.; Vacca, A.; Stoppacciaro, A.; Modesti, A.; Forni, G. Role of neutrophils
and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary
adenocarcinoma made immunogenic by IL-2 gene. J. Immunol. 1992, 149, 3627–3635. [PubMed]
55. Musiani, P.; Alione, A.; Modica, A.; Lollini, P.L.; Giovarelli, M.; Cavallo, F.; Belardelli, F.; Forni, G.; Modesti, A.
Role of Neutrophils and Lymphocytes in Inhibition of a Mouse Mammary Adenocarcinoma Engineered to
Release IL-2, IL-4, IL-7, IL-10, IFN-α, IFN-γ, and TNF-α. Lab. Investig. 1996, 74, 146–157.
56. Meazza, R.; Marciano, S.; Sforzini, S.; Orengo, A.; Coppolecchia, M.; Musiani, P.; Ardizzoni, A.; Santi, L.;
Azzarone, B.; Ferrini, S. Analysis of IL-2 receptor expression and of the biological effects of IL-2 gene
transfection in small-cell lung cancer. Br. J. Cancer 1996, 74, 788–795. [CrossRef]
57. Girard, D.; Gosselin, J.; Heitz, D.; Paquin, R.; Beaulieu, A.D. Effects of interleukin-2 on gene expression in
human neutrophils. Blood 1995, 86, 1170–1176. [CrossRef]
58. Li, J.; Gyorffy, S.; Lee, S.; Kwok, C.S. Effect of recombinant human interleukin 2 on neutrophil adherence to
endothelial cells in vitro. Inflammation 1996, 20, 361–372. [CrossRef]
59. Comen, E.; Wojnarowicz, P.; Seshan, V.E.; Shah, R.; Coker, C.; Norton, L.; Benezra, R. TNF is a key cytokine
mediating neutrophil cytotoxic activity in breast cancer patients. NPJ Breast Cancer 2016, 2, 16009. [CrossRef]
60. Finisguerra, V.; Di Conza, G.; Di Matteo, M.; Serneels, J.; Costa, S.; Thompson, A.A.R.; Wauters, E.;
Walmsley, S.; Prenen, H.; Granot, Z.; et al. MET is required for the recruitment of anti-tumoural neutrophils.
Nat. Cell Biol. 2015, 522, 349–353. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 7820 23 of 34
61. Mantovani, A. The Yin-Yang of Tumor-Associated Neutrophils. Cancer Cell 2009, 16, 173–174. [CrossRef]
[PubMed]
62. Shen, L.; Smith, J.M.; Shen, Z.; Eriksson, M.; Sentman, C.; Wira, C.R. Inhibition of human neutrophil
degranulation by transforming growth factor-β. Clin. Exp. Immunol. 2007, 149, 155–161. [CrossRef]
[PubMed]
63. Granot, Z.; Henke, E.; Comen, E.A.; King, T.A.; Norton, L.; Benezra, R. Tumor Entrained Neutrophils Inhibit
Seeding in the Premetastatic Lung. Cancer Cell 2011, 20, 300–314. [CrossRef] [PubMed]
64. Qin, F.; Liu, X.; Chen, J.; Huang, S.; Wei, W.; Zou, Y.; Liu, X.; Deng, K.; Mo, S.; Chen, J.; et al. Anti-TGF-β
attenuates tumor growth via polarization of tumor associated neutrophils towards an anti-tumor phenotype
in colorectal cancer. J. Cancer 2020, 11, 2580–2592. [CrossRef] [PubMed]
65. Balazovich, K.J.; Fernandez, R.; Hinkovska-Galcheva, V.; Suchard, S.J.; Boxer, L.A. Transforming growth
factor-β1 stimulates degranulation and oxidant release by adherent human neutrophils. J. Leukoc. Biol. 1996,
60, 772–777. [CrossRef] [PubMed]
66. Haider, C.; Hnat, J.; Wagner, R.; Huber, H.; Timelthaler, G.; Grubinger, M.; Coulouarn, C.; Schreiner, W.;
Schlangen, K.; Sieghart, W.; et al. Transforming Growth Factor-β and Axl Induce CXCL5 and Neutrophil
Recruitment in Hepatocellular Carcinoma. Hepatology 2019, 69, 222–236. [CrossRef]
67. Guerin, M.V.; Regnier, F.; Feuillet, V.; Vimeux, L.; Weiss, J.M.; Bismuth, G.; Altan-Bonnet, G.; Guilbert, T.;
Thoreau, M.; Finisguerra, V.; et al. TGFβ blocks IFNα/β release and tumor rejection in spontaneous mammary
tumors. Nat. Commun. 2019, 10, 1–12. [CrossRef]
68. Pylaeva, E.; Lang, S.; Jablonska, J. The essential role of type I interferons in differentiation and activation of
tumor-associated neutrophils. Front. Immunol. 2016, 7, 629. [CrossRef] [PubMed]
69. Jablonska, J.; Leschner, S.; Westphal, K.; Lienenklaus, S.; Weiss, S. Neutrophils responsive to endogenous
IFN-β regulate tumor angiogenesis and growth in a mouse tumor model. J. Clin. Investig. 2010, 120,
1151–1164. [CrossRef]
70. Bekisz, J.; Baron, S.; Balinsky, C.; Morrow, A.; Zoon, K.C. Antiproliferative Properties of Type I and Type II
Interferon. Pharmaceuticals 2010, 3, 994–1015. [CrossRef]
71. Qin, X.-Q.; Tao, N.; Dergay, A.; Moy, P.; Fawell, S.; Davis, A.; Wilson, J.M.; Barsoum, J. Interferon- gene
therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice.
Proc. Natl. Acad. Sci. USA 1998, 95, 14411–14416. [CrossRef] [PubMed]
72. Prantner, D.; Perkins, D.J.; Lai, W.; Williams, M.S.; Sharma, S.; Fitzgerald, K.A.; Vogel, S.N.
5,6-Dimethylxanthenone-4-acetic Acid (DMXAA) Activates Stimulator of Interferon Gene (STING)-dependent
Innate Immune Pathways and Is Regulated by Mitochondrial Membrane Potential. J. Biol. Chem. 2012, 287,
39776–39788. [CrossRef] [PubMed]
73. Henkels, K.M.; Frondorf, K.; Gonzalez-Mejia, M.E.; Doseff, A.L.; Gomez-Cambronero, J. IL-8-induced
neutrophil chemotaxis is mediated by Janus kinase 3 (JAK3). FEBS Lett. 2011, 585, 159–166. [CrossRef]
[PubMed]
74. Altstaedt, J.; Kirchner, H.; Rink, L. Cytokine production of neutrophils is limited to interleukin-8. Immunology
1996, 89, 563–568. [CrossRef] [PubMed]
75. De Larco, J.E.; Wuertz, B.R.K.; Furcht, L.T. The Potential Role of Neutrophils in Promoting the Metastatic
Phenotype of Tumors Releasing Interleukin-8. Clin. Cancer Res. 2004, 10, 4895–4900. [CrossRef] [PubMed]
76. Yuen, K.C.; Liu, L.-F.; Gupta, V.; Madireddi, S.; Keerthivasan, S.; Li, C.; Rishipathak, D.; Williams, P.;
Kadel, E.E.; Koeppen, H.; et al. High systemic and tumor-associated IL-8 correlates with reduced clinical
benefit of PD-L1 blockade. Nat. Med. 2020, 26, 693–698. [CrossRef] [PubMed]
77. López-Lago, M.A.; Posner, S.; Thodima, V.J.; Molina, A.M.; Motzer, R.J.; Chaganti, R.S.K. Neutrophil
chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma
progression. Oncogene 2013, 32, 1752–1760. [CrossRef]
78. Jablonska, J.; Wu, C.-F.; Andzinski, L.; Leschner, S.; Weiss, S. CXCR2-mediated tumor-associated neutrophil
recruitment is regulated by IFN-β. Int. J. Cancer 2014, 134, 1346–1358. [CrossRef]
79. Shi, F.-S.; Weber, S.; Gan, J.; Rakhmilevich, A.L.; Mahvi, D.M. Granulocyte-macrophage colony-stimulating
factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than
exogenous GM-CSF. Cancer Gene Ther. 1999. [CrossRef]
80. Gale, R.P.; Zighelboim, J. Polymorphonuclear leukocytes in antibody-dependent cellular cytotoxicity. J.
Immunol. 1975, 114, 1047–1051.
Int. J. Mol. Sci. 2020, 21, 7820 24 of 34
81. Petroni, K.C.; Shen, L.; Guyre, P.M. Modulation of human polymorphonuclear leukocyte IgG Fc receptors
and Fc receptor-mediated functions by IFN-gamma and glucocorticoids. J. Immunol. 1988, 140, 3467–3472.
[PubMed]
82. Matlung, H.L.; Babes, L.; Zhao, X.W.; Van Houdt, M.; Treffers, L.W.; Van Rees, D.J.; Franke, K.; Schornagel, K.;
Verkuijlen, P.; Janssen, H.; et al. Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis. Cell Rep.
2018, 23, 3946–3959. [CrossRef] [PubMed]
83. Anderson, C.L.; Shen, L.; Eicher, D.M.; Wewers, M.D.; Gill, J.K. Phagocytosis mediated by three distinct Fcγ
receptor classes on human leukocytes. J. Exp. Med. 1990. [CrossRef] [PubMed]
84. Golay, J.; Valgardsdottir, R.; Musaraj, G.; Giupponi, D.; Spinelli, O.; Introna, M. Human neutrophils express
low levels of FcγRIIIA, which plays a role in PMN activation. Blood 2019, 133, 1395–1405. [CrossRef]
[PubMed]
85. Chen, K.; Nishi, H.; Travers, R.; Tsuboi, N.; Martinod, K.; Wagner, D.D.; Stan, R.; Croce, K.; Mayadas, T.N.
Endocytosis of soluble immune complexes leads to their clearance by FcγRIIIB but induces neutrophil
extracellular traps via FcγRIIA in vivo. Blood 2012, 120, 4421–4431. [CrossRef] [PubMed]
86. Alevy, Y.G.; Tucker, J.; Naziruddin, B.; Mohanakumar, T. CD32C (Fcγ RIIC) mRNA expression and regulation.
Mol. Immunol. 1993, 30, 775–782. [CrossRef]
87. Su, K.; Yang, H.; Li, X.; Li, X.; Gibson, A.W.; Cafardi, J.M.; Zhou, T.; Edberg, J.C.; Kimberly, R.P. Expression
Profile of FcγRIIb on Leukocytes and Its Dysregulation in Systemic Lupus Erythematosus. J. Immunol. 2007,
178, 3272–3280. [CrossRef]
88. Treffers, L.W.; Van Houdt, M.; Bruggeman, C.W.; Heineke, M.H.; Zhao, X.W.; Van Der Heijden, J.;
Nagelkerke, S.Q.; Verkuijlen, P.J.J.H.; Geissler, J.; Lissenberg-Thunnissen, S.; et al. FcγRIIIb Restricts
Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils. Front. Immunol. 2019. [CrossRef]
89. Treffers, L.W.; Zhao, X.W.; Van Der Heijden, J.; Nagelkerke, S.Q.; Van Rees, D.J.; Gonzalez, P.; Geissler, J.;
Verkuijlen, P.; Van Houdt, M.; De Boer, M.; et al. Genetic variation of human neutrophil Fcγ receptors and
SIRPα in antibody-dependent cellular cytotoxicity towards cancer cells. Eur. J. Immunol. 2018, 48, 344–354.
[CrossRef]
90. Kerntke, C.; Nimmerjahn, F.; Biburger, M. There Is (Scientific) Strength in Numbers: A Comprehensive
Quantitation of Fc Gamma Receptor Numbers on Human and Murine Peripheral Blood Leukocytes. Front.
Immunol. 2020. [CrossRef]
91. Kerst, J.J.; van de Winkel, J.G.; Evans, A.H.; de Haas, M.; Slaper-Cortenbach, I.C.; de Wit, T.P.; Borne, A.E.V.;
van der Schoot, C.E.; van Oers, R.H. Granulocyte colony-stimulating factor induces hFc gamma RI (CD64
antigen)-positive neutrophils via an effect on myeloid precursor cells. Blood 1993, 81, 1457–1464. [CrossRef]
92. Gericke, G.H.; Ericson, S.G.; Pan, L.; Mills, L.E.; Guyre, P.M.; Ely, P. Mature polymorphonuclear leukocytes
express high-affinity receptors for IgG (FcγRI) after stimulation with granulocyte colony-stimulating factor
(G-CSF). J. Leukoc. Biol. 1995, 57, 455–461. [CrossRef] [PubMed]
93. Perussia, B.; Dayton, E.T.; Lazarus, R.; Fanning, V.; Trinchieri, G. Immune interferon induces the receptor for
monomeric IgG1 on human monocytic and myeloid cells. J. Exp. Med. 1983, 158, 1092–1113. [CrossRef]
[PubMed]
94. Bibeau, F.; Lopez-Crapez, E.; Di Fiore, F.; Thezenas, S.; Ychou, M.; Blanchard, F.; Lamy, A.; Penault-Llorca, F.;
Frébourg, T.; Michel, P.; et al. Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the
Clinical Outcome of Patients with Metastatic Colorectal Cancer Treated with Cetuximab Plus Irinotecan. J.
Clin. Oncol. 2009, 27, 1122–1129. [CrossRef] [PubMed]
95. Weng, W.-K.; Levy, R. Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict
Response to Rituximab in Patients with Follicular Lymphoma. J. Clin. Oncol. 2003, 21, 3940–3947. [CrossRef]
[PubMed]
96. Musolino, A.; Naldi, N.; Bortesi, B.; Pezzuolo, D.; Capelletti, M.; Missale, G.; Laccabue, D.; Zerbini, A.;
Camisa, R.; Bisagni, G.; et al. Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy
of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer. J. Clin. Oncol.
2008, 26, 1789–1796. [CrossRef] [PubMed]
97. Zhang, W.; Gordon, M.; Schultheis, A.M.; Yang, D.Y.; Nagashima, F.; Azuma, M.; Chang, H.-M.; Borucka, E.;
Lurje, G.; Sherrod, A.E.; et al. FCGR2A and FCGR3A Polymorphisms Associated with Clinical Outcome
of Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Cancer Patients Treated with
Single-Agent Cetuximab. J. Clin. Oncol. 2007, 25, 3712–3718. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 7820 25 of 34
98. Shashidharamurthy, R.; Zhang, F.; Amano, A.; Kamat, A.; Panchanathan, R.; Ezekwudo, D.; Zhu, C.;
Selvaraj, P. Dynamics of the Interaction of Human IgG Subtype Immune Complexes with Cells Expressing R
and H Allelic Forms of a Low-Affinity Fcγ Receptor CD32A. J. Immunol. 2009, 183, 8216–8224. [CrossRef]
99. Hurvitz, S.A.; Betting, D.J.; Stern, H.M.; Quinaux, E.; Stinson, J.; Seshagiri, S.; Zhao, Y.; Buyse, M.; Mackey, J.;
Driga, A.; et al. Analysis of Fc Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in
Trastuzumab-Treated Breast Cancer Patients. Clin. Cancer Res. 2012, 18, 3478–3486. [CrossRef]
100. Amigorena, S.; Bonnerot, C.; Choquet, D.; Hunziker, W.; Guillet, J.; Webster, P.; Sautes, C.; Mellman, I.;
Fridman, W.H. Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes.
Science 1992, 256, 1808–1812. [CrossRef]
101. Ravetch, J.V. Fc receptors. Curr. Opin. Immunol. 1997, 9, 121–125. [CrossRef]
102. Vidarsson, G.; Van De Winkel, J.G. Fc receptor and complement receptor-mediated phagocytosis in host
defence. Curr. Opin. Infect. Dis. 1998, 11, 271–278. [CrossRef] [PubMed]
103. Golay, F.J.; Da Roit, L.; Bologna, C.; Ferrara, C.K.; Leusen, J.H.; Rambaldi, A.; Martino, I. Glycoengineered
CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more
efficiently than rituximab. Blood 2013, 122, 3482–3491. [CrossRef] [PubMed]
104. Derer, S.; Glorius, P.; Schlaeth, M.; Lohse, S.; Klausz, K.; Muchhal, U.; DesJarlais, J.R.; Humpe, A.;
Valerius, T.; Peipp, M. Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores
neutrophil-mediated cytotoxicity. mAbs 2014, 6, 409–421. [CrossRef] [PubMed]
105. Dekkers, G.; Treffers, L.; Plomp, R.; Bentlage, A.E.H.; De Boer, M.; Koeleman, C.A.M.;
Lissenberg-Thunnissen, S.N.; Visser, R.; Brouwer, M.; Mok, J.Y.; et al. Decoding the Human Immunoglobulin
G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities.
Front. Immunol. 2017, 8, 877. [CrossRef] [PubMed]
106. Subedi, G.P.; Hanson, Q.M.; Barb, A.W. Restricted Motion of the Conserved Immunoglobulin G1 N-Glycan
Is Essential for Efficient FcγRIIIa Binding. Structure 2014, 22, 1478–1488. [CrossRef] [PubMed]
107. Ferrara, C.; Grau, S.; Jäger, C.; Sondermann, P.; Brünker, P.; Waldhauer, I.; Hennig, M.; Ruf, A.; Rufer, A.C.;
Stihle, M.; et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding
between Fc RIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. USA 2011, 108, 12669–12674.
[CrossRef] [PubMed]
108. Peipp, M.; Van Bueren, J.J.L.; Schneider-Merck, T.; Bleeker, W.W.K.; DeChant, M.; Beyer, T.; Repp, R.; Van
Berkel, P.H.C.; Vink, T.; Van De Winkel, J.G.J.; et al. Antibody fucosylation differentially impacts cytotoxicity
mediated by NK and PMN effector cells. Blood 2008, 112, 2390–2399. [CrossRef]
109. Shibata-Koyama, M.; Iida, S.; Misaka, H.; Mori, K.; Yano, K.; Shitara, K.; Satoh, M. Nonfucosylated rituximab
potentiates human neutrophil phagocytosis through its high binding for FcγRIIIb and MHC class II expression
on the phagocytotic neutrophils. Exp. Hematol. 2009, 37, 309–321. [CrossRef] [PubMed]
110. Marcus, R.; Davies, A.; Ando, K.; Klapper, W.; Opat, S.; Owen, C.; Phillips, E.; Sangha, R.; Schlag, R.;
Seymour, J.F.; et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N. Engl. J. Med.
2017, 377, 1331–1344. [CrossRef]
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